Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1031

1.

Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.

Krikken JA, Waanders F, Dallinga-Thie GM, Dikkeschei LD, Vogt L, Navis GJ, Dullaart RP.

Expert Opin Ther Targets. 2009 May;13(5):497-504. doi: 10.1517/14728220902905865 .

PMID:
19397474
2.

Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients.

Dullaart RP, Gansevoort RT, Dikkeschei BD, de Zeeuw D, de Jong PE, Van Tol A.

Kidney Int. 1993 Jul;44(1):91-7.

PMID:
8355471
4.

Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.

Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL.

Clin Endocrinol (Oxf). 2008 Dec;69(6):870-7. doi: 10.1111/j.1365-2265.2008.03250.x. Epub 2008 Apr 3.

PMID:
18394022
5.

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.

de Zeeuw D, Gansevoort RT, Dullaart RP, de Jong PE.

J Hypertens Suppl. 1995 Jul;13(1):S53-8.

PMID:
18800457
6.

Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.

Vogt L, Laverman GD, van Tol A, Groen AK, Navis G, Dullaart RP.

Nephrol Dial Transplant. 2006 Jan;21(1):101-6. Epub 2005 Sep 2.

7.

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.

Expert Opin Ther Targets. 2009 Jul;13(7):743-51. doi: 10.1517/14728220903023866.

PMID:
19505224
8.

Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment.

de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP.

Diabetologia. 2005 Jun;48(6):1105-13. Epub 2005 May 5.

PMID:
15875154
9.

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

Seiler S, Schlitt A, Jiang XC, Ulrich C, Blankenberg S, Lackner KJ, Girndt M, Werdan K, Buerke M, Fliser D, Heine GH.

Nephrol Dial Transplant. 2008 Nov;23(11):3599-604. doi: 10.1093/ndt/gfn296. Epub 2008 May 25.

10.

Cholesteryl ester transfer protein in metabolic syndrome.

Sandhofer A, Kaser S, Ritsch A, Laimer M, Engl J, Paulweber B, Patsch JR, Ebenbichler CF.

Obesity (Silver Spring). 2006 May;14(5):812-8.

PMID:
16855190
11.
12.
13.

Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy.

Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP.

Scand J Clin Lab Invest. 2000 May;60(3):189-98.

PMID:
10885490
15.

Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).

Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ.

Eur J Clin Invest. 2004 Jan;34(1):21-8.

PMID:
14984434
18.
19.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

20.

Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.

Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G.

Circulation. 2003 Feb 4;107(4):586-92.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk